コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 elial ovarian cancers were identified (3,378 serous, 606 endometrioid, 331 mucinous, 269 clear cell,
2 ssociation between GSN expression in ovarian serous adenocarcinoma and progression free survival and
3 rowth of three of five lethal chemoresistant serous adenocarcinoma PDXa models without signs of measu
8 lts highlight mutational differences between serous and non-serous ovarian cancers, and further disti
11 ith both nonvascularized PEDs (drusenoid and serous) and vascularized PEDs (type 1 and type 3 neovasc
15 visualization of fine papillary branches in serous BOT and allowed for characterization of spatial f
17 loss is a hallmark of the earliest stages of serous carcinogenesis and occurs both at the DNA, RNA an
18 molecular aberration in the FTE occurring in serous carcinogenesis followed by a mutation in p53.
20 r cell carcinoma (Arid1a, Pik3ca), low-grade serous carcinoma (Braf), endometrioid (Ctnnb1), or mucin
22 g evidence indicates that ovarian high-grade serous carcinoma (HGSC) originates from fallopian tube s
23 lantable murine models of ovarian high grade serous carcinoma (HGSC) remain an important research too
25 lantable murine models of ovarian high-grade serous carcinoma (HGSC) with regard to mutations in the
26 cantly increased risk for ovarian high-grade serous carcinoma (HGSC; 3.8% cases vs. 0.2% controls).
29 ate that the precursor of ovarian high-grade serous carcinoma appears to develop from an occult intra
33 ation of chemotherapy in ovarian and uterine serous carcinoma patients by biodegradable nanoparticles
34 among patients with stage II to IV low-grade serous carcinoma treated with primary surgery followed b
35 nclusion Women with stage II to IV low-grade serous carcinoma who received HMT after primary treatmen
36 common subtype of ovarian cancer, high-grade serous carcinoma, has sparked a major effort within the
39 against i.p. chemotherapy-resistant uterine serous carcinoma-derived xenografts compared with free E
42 al fallopian tube among all cases.High-grade serous carcinomas (HGSCs) are associated with precursor
45 ian tumors (BOT) can progress into low-grade serous carcinomas and have relatively indolent clinical
47 en observed at high frequency in endometrial serous carcinomas but at low frequency in ovarian clear
48 ated endometrioid, clear cell, and low-grade serous carcinomas from high-grade serous and mucinous ca
50 cular pathogenesis of fallopian tube-derived serous carcinomas is poorly understood and there are few
52 e composed, for the most part, of high-grade serous carcinomas that can be further subdivided into mo
55 , and seromucinous carcinomas; ii) low-grade serous carcinomas; and iii) mucinous carcinomas and mali
66 to a fifth of patients with chronic central serous chorioretinopathy but carry a relatively good vis
67 three eyes of 30 patients with acute central serous chorioretinopathy comprised the comparative group
68 eyes; severe cough in 1.9% of eyes; central serous chorioretinopathy in 1.4% of eyes; intraocular le
70 Consecutive patients with chronic central serous chorioretinopathy were identified from the clinic
72 preceding 2 years, had a history of central serous chorioretinopathy, and did not have a history of
73 tion of fluid is a common finding in central serous chorioretinopathy, but it has a different pattern
75 oroidal vascular changes, similar to central serous chorioretinopathy, but specifically confined in t
76 pairment of the photoreceptor layer (central serous chorioretinopathy, chronic central serous chorior
77 al serous chorioretinopathy, chronic central serous chorioretinopathy, maculopathy associated with hy
78 retinal vein occlusion (CRVO/BRVO), central serous chorioretinopathy, vitreomacular traction, and fu
79 utive cohort of patients, with acute central serous chorioretinopathy, was also examined for the pres
83 ors and compared our results to TCGA ovarian serous cystadenocarcinoma and uterine corpus endometrial
88 Although many cysts, such as pseudocysts and serous cystadenomas, are benign and can be monitored cli
89 cinous neoplasms, mucinous cystic neoplasms, serous cystadenomas, solid pseudopapillary neoplasms, cy
90 f vision, presence of subretinal hemorrhage, serous detachment, retinal pigment epithelial detachment
93 tures of AEPVM, including initial localized, serous detachments followed by the development of charac
96 ignaling, illuminating the genetic basis for serous EC development and its potential control by ratio
97 r light chain deposition disease may develop serous elevations of the macula that we classify as acqu
98 genomic alterations that occur frequently in serous endometrial carcinoma (EC) and carcinosarcoma, tw
102 y loci for different EOC histotypes: six for serous EOC histotypes (3q28, 4q32.3, 8q21.11, 10q24.33,
104 Kras(G12D)-mutant mouse strain that develops serous EOC with 100% penetrance to introduce the mutant
107 tations in non-serous was much lower than in serous epithelial OC, whereas the prevalence of PIK3CA,
109 dies have revealed the mutation landscape of serous epithelial ovarian cancer, other non-serous subty
110 Here we conduct exome sequencing of nine non-serous epithelial ovarian tumors (six endometrioid and t
111 te a 30-40-fold increased risk of high-grade serous extra-uterine Mullerian cancers (HGSEMC), otherwi
113 r cell lines, 14 were assigned as high-grade serous, four serous-type, one low-grade serous and 20 no
114 n any gene were more likely to be high grade serous, have an earlier diagnosis age and have ovarian a
115 ms underlying clinical outcome of high-grade serous (HGS) epithelial ovarian carcinomas (EOC), we eva
117 d the prognostic value of CD73 in high-grade serous (HGS) ovarian cancer using gene and protein expre
118 opean descent, including 6,179 of high-grade serous (HGS), 2,100 endometrioid, 1,591 mucinous, 1,034
119 rer survival included: clear/mucinous versus serous histology (AHR, 2.79; 95% CI, 1.83 to 4.24; P < .
121 inous, 1,034 clear cell, and 1,016 low-grade serous, including 23,235 control cases spanning 40 studi
122 iation for flavanone intake was stronger for serous invasive and poorly differentiated tumors (compar
123 t potential and should be distinguished from serous lesions (serous cystadenomas) that are nearly alw
127 l sutureless pars plana vitrectomy (PPV) for serous macular detachment associated with optic disc pit
128 mopathy-producing pathologic antibodies with serous macular detachment being an uncommon ocular manif
129 safe and effective method for management of serous macular detachment resulting from optic disc pits
131 er retinal schisis; 2 of them had associated serous macular detachment while inner retinal schisis wa
132 To test this novel therapeutic peptide, serous malignant ascites from highly resistant recurrent
133 year, the therapy was started again and the serous neuroretinal detachment appeared once more, howev
135 ify 13 candidate causal SNPs associated with serous OC (P=9.2 x 10(-20)), ER-negative BC (P=1.1 x 10(
137 with recurrent platinum-sensitive high-grade serous or endometrioid ovarian cancer, and warrants stud
138 ble platinum-sensitive, relapsed, high-grade serous or endometrioid ovarian, fallopian tube, or prima
139 older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or f
140 loiting the sidedness of BP scaffolds (i.e., serous or fibrous surface), this study aims to determine
142 sorder, receptive language disorder, chronic serous otitis media, and expressive language disorder.
143 n important role in the growth of high-grade serous ovarian (HGS-OvCa) and other cancers, but its cli
144 algorithms and used them with 296 high-grade serous ovarian (HGS-OvCa) tumor and 1,839 normal RNA-seq
145 alignancy in the United States, and advanced serous ovarian adenocarcinoma is responsible for most ov
148 BRCA2 mutations in patients with high-grade serous ovarian cancer (HGSC) are associated with favorab
154 mor tissue from 158 patients with high-grade serous ovarian cancer (HGSOC) and 100 control patients w
155 ted tomography (CT) phenotypes of high-grade serous ovarian cancer (HGSOC) and to evaluate CT indicat
156 cal challenge in the treatment of high-grade serous ovarian cancer (HGSOC) is the development of prog
157 repressed in approximately 30% of high-grade serous ovarian cancer (HGSOC) patients and is a recurren
158 cell line representative of human high-grade serous ovarian cancer (HGSOC) should not only resemble i
159 mography (CT) imaging features of high-grade serous ovarian cancer (HGSOC), to assess their associati
160 etermine early somatic changes in high-grade serous ovarian cancer (HGSOC), we performed whole genome
163 uded 244 patients with pathologically proven serous ovarian cancer (mean age +/- standard deviation,
165 cedes the radiologic detection of high-grade serous ovarian cancer by at least 2 mo and the final cli
169 est DESI-MS as a powerful approach for rapid serous ovarian cancer diagnosis based on altered metabol
172 stologically confirmed, relapsed, high-grade serous ovarian cancer or high-grade endometrioid cancer,
175 th BRCA-mutated platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance mon
176 etic testing to all patients with high-grade serous ovarian cancer regardless of family history.
177 We performed an analysis of CNV data of 587 serous ovarian cancer samples on multiple platforms.
178 line and as small as 9 Mb in two high-grade serous ovarian cancer samples using only 0.02x depth.
179 d multi-omics profiles of primary high-grade serous ovarian cancer tumours (N=357) to delineate mecha
180 romal gene signature for advanced high-grade serous ovarian cancer using microdissected stromal ovari
181 l siRNA delivery system and a mouse model of serous ovarian cancer were used to test predictions from
182 , patients with platinum-sensitive recurrent serous ovarian cancer who had received two or more cours
183 n patients with platinum-sensitive recurrent serous ovarian cancer who had received two or more plati
184 th platinum-sensitive, recurrent, high-grade serous ovarian cancer who had received up to three previ
185 t patients with platinum-sensitive recurrent serous ovarian cancer with a BRCA mutation have the grea
186 th platinum-sensitive, recurrent, high-grade serous ovarian cancer with or without BRCA1 or BRCA2 mut
187 meta-analysis on the results for high-grade serous ovarian cancer with the results from analysis of
188 ) (CaMKK2) is highly expressed in high-grade serous ovarian cancer, and we investigated its role in A
189 n patients with platinum-sensitive recurrent serous ovarian cancer, including those with BRCA1 and BR
190 n patients with platinum-sensitive recurrent serous ovarian cancer, maintenance monotherapy with the
191 xceptional case of a patient with high-grade serous ovarian cancer, treated with multiple chemotherap
192 aluated as a diagnostic probe for high-grade serous ovarian cancer, typically diagnosed at late stage
193 development of drug resistance in high-grade serous ovarian cancer, were examined from patient derive
205 erformed phylogenetic analysis of high-grade serous ovarian cancers (68 samples from seven patients),
206 ance in ovarian and other cancers.High-grade serous ovarian cancers (HGS-OvCa) frequently develop che
207 k of effective chemotherapies for high-grade serous ovarian cancers (HGS-OvCa) has motivated a search
209 , the debated cellular origins of high-grade serous ovarian cancers (HGSOCs) and in endometriosis epi
211 amplified with PIK3CA in 29.3% of high-grade serous ovarian cancers and its overexpression is signifi
213 CAPRO underestimated the risk for high-grade serous ovarian cancers but overestimated the risk for ot
214 utational differences between serous and non-serous ovarian cancers, and further distinguish differen
224 s a candidate oncogenic driver in high-grade serous ovarian carcinoma, we evaluated the functional ro
230 nes and in organoids derived from high-grade serous ovarian carcinomas (HGSOC), an aggressive cancer
233 aberrations to those observed in high-grade serous ovarian carcinomas suggests that genetic biomarke
238 rotein levels were upregulated in high-grade serous ovarian patient tumors, where the FoxM1 signature
239 involvement in cancer from additional 28 non-serous ovarian tumors and compared our results to TCGA o
240 eceptor expression in a tissue microarray of serous ovarian tumors by immunohistochemistry and found
241 Many cancers, however, including high-grade serous ovarian, oesophageal, and small-cell lung cancer,
242 on pathways associated with chemoresponse in serous OVCA in three independent gene-expression experim
244 er PED at baseline (P = .001), predominantly serous PED (P = .003), and the use of aflibercept (P = .
245 The volume of the migrated RPE cluster in serous PED was significantly correlated with the volume
246 noid pigment epithelial detachment (PED) and serous PED with significantly higher frequencies than in
247 k choroid and predominantly nonvascularized, serous PEDs with an overlying neurosensory detachment.
248 l window of opportunity to detect high-grade serous peritoneal carcinoma arising from the fallopian t
258 Main outcome measures included resolution of serous retinal detachment (SRD) with single PDT, change
261 loped bilateral anterior uveitis and macular serous retinal detachment during nivolumab treatment for
264 ral anterior uveitis associated with macular serous retinal detachment related to anti-PD-1 treatment
268 omography, dilation of choroidal vessels and serous retinal detachments (SRDs) were observed and conf
269 their metastatic cancer, who had evidence of serous retinal detachments confirmed by optical coherenc
271 an Eye and Ear Hospital with acute bilateral serous retinal detachments without anterior chamber infl
272 clinical and morphologic characteristics of serous retinal disturbances in patients taking mitogen-a
273 ystic changes, choroidal neovascularization, serous retinal elevations mimicking retinal folds, incre
278 r after RRSO was not increased, the risk for serous/serous-like endometrial carcinoma was increased i
282 etion occurs predominantly in poor prognosis serous subtype tumours, and this genetic deletion is ass
283 serous epithelial ovarian cancer, other non-serous subtypes of the disease have not been explored as
288 cted fallopian tube lesions (p53 signatures, serous tubal intraepithelial carcinomas (STICs), and fal
289 veloping from small precursor lesions called serous tubal intraepithelial carcinomas (TICs, or more s
290 nonsignificantly increased risk of low-grade serous tumors (pOR = 1.48, 95% CI: 0.92, 2.38) was noted
294 iltrating lymphocytes (TILs) from high-grade serous tumors, defined their suppressive capacity in vit
298 14 were assigned as high-grade serous, four serous-type, one low-grade serous and 20 non-serous type
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。